Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Citigroup Inc. to a "market perform" rating.MarketBeat
- Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025PR Newswire
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $1.00 price target on the stock, down previously from $5.00.MarketBeat
- Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.MarketBeat
ELEV
Sec Filings
- 3/26/25 - Form SCHEDULE
- 3/20/25 - Form 8-K
- 3/19/25 - Form 8-K
- ELEV's page on the SEC website